4,8-二甲基-2-乙氧基喹啉 | 15113-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4,8-二甲基-2-乙氧基喹啉
• 英文名称: 2-Ethoxy-4,8-dimethylquinoline
• CAS: 15113-01-6
• 化学式: C₁₃H₁₅NO
• 分子量: 201.26
• InChiKey: MYOOFSYPOPYDJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] HEPATITIS C INHIBITOR PEPTIDE ANALOGS<br/>[FR] ANALOGUES PEPTIDIQUES D'INHIBITEURS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006000085A1

  公开（公告）日：2006-01-05

  The invention relates to compounds of formula (I) wherein R', R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).

  本发明涉及式(I)的化合物，其中R'，R2，R3，R4，R5，R6，Y，n和m如本文所述定义。这些化合物通过抑制HCV NS3蛋白酶，用于治疗和预防哺乳动物中的丙型肝炎病毒感染。本发明进一步涉及可以与酰胺阴离子反应以产生式(I)化合物的azalactone化合物（III）。
• MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
  申请人：Raboisson Pierre Jean-Marie

  公开号：US20100022578A1

  公开（公告）日：2010-01-28

  Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein each dashed line (represented by represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1 is —OR 7 , —NH—SO 2 R 8 ; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 3-7 cycloalkyl; n is 3, 4, 5, or 6; R 4 is C 1-6 alkyl or C 3-7 cycloalkyl; R 5 is hydrogen, halo, C 1-6 alkyl, hydroxy, C 1-6 alkoxy, polyhaloC 1-6 alkyl; R 6 is hydrogen, C 1-6 alkoxy, mono- or diC 1-6 alkylamino; or R 5 and R 6 may form a 5- or 6-membered unsaturated or partially unsaturated ring, optionally comprising one or two selected from O, N and S; R 7 is hydrogen; C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; or C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl; R 8 is C 3-7 cycloalkyl optionally substituted with C 1-6 alkyl; C 1-6 alkyl optionally substituted with C 3-7 cycloalkyl; or —NR 8a R 8b ; R 8a and R 8b are C 1-6 alkyl, or both may form a 5- or 6-membered saturated heterocyclic ring; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).

  公式（I）及其盐和立体异构体的HCV复制抑制剂，其中每个虚线（由表示可选双键）; X为N，CH，其中X带有双键时为C; R1为—OR7，—NH—SO2R8; R2为氢，当X为C或CH时，R2也可以是C1-6烷基; R3为氢，C1-6烷基，C1-6烷氧基C1-6烷基，C3-7环烷基; n为3、4、5或6; R4为C1-6烷基或C3-7环烷基; R5为氢，卤素，C1-6烷基，羟基，C1-6烷氧基，多卤素C1-6烷基; R6为氢，C1-6烷氧基，单烷基或二烷基氨基; 或R5和R6可以形成一个5-或6-成员的不饱和或部分不饱和环，可选地包括O、N和S中的一个或两个; R7为氢; C3-7环烷基，可选地被C1-6烷基取代; 或C1-6烷基，可选地被C3-7环烷基取代; R8为C3-7环烷基，可选地被C1-6烷基取代; C1-6烷基，可选地被C3-7环烷基取代; 或—NR8aR8b; R8a和R8b为C1-6烷基，或两者可以形成一个5-或6-成员的饱和杂环; 包含化合物（I）的制药组合物和制备化合物（I）的方法。
• US8637663B2
  申请人：——

  公开号：US8637663B2

  公开（公告）日：2014-01-28
• US9365582B2
  申请人：——

  公开号：US9365582B2

  公开（公告）日：2016-06-14